BioSpace News Archive

Subsidiary focused on next generation DNA-based biotherapeutics and powered by a portfolio of intellectual property

After reacquiring itself from Nokia on May 31, 2018, Withings is back with a new look, a strengthened focus on connected health and the first new product under its original brand.

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announces that since dosing the first subject on June 27, 2017, 25% of the planned subjects received treatment in its Phase 2 study of dextromethadone (REL-1017) in depression

Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the completion of a $2.7M financing effort, which includes an over-subscribed $2M round in venture-backed capital and over $670K in non-dilutive capital

The 2019 Bridging Clinical Research & Clinical Health Care Collaborative will convene March 4–5, 2019, at the National Academy of Sciences in Washington, D.C.

First In Human Experience to be Presented at TCT 2018

Former Co-CEO Adi Mohanty to Aid in Transition and Continue to Serve on the Boards of Asterias and OncoCyte

The investment will support the continued development of AtaCor’s revolutionary extravascular substernal cardiac pacing system.

Invitae Corporation today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern / 6:00 a.m. Pacific in New York City.

Syncroness is excited to announce that Vice President of Engineering, Todd Mosher, will present Syncroness’ cutting-edge Agile methodology for space hardware design at this year’s AIAA Space Forum on September 18, 2018.